1,000
Participants
Start Date
April 1, 2022
Primary Completion Date
March 31, 2025
Study Completion Date
December 1, 2025
operation
operation methods: breast-conserving surgery, mastectomy, axillary lymph node dissection, sentinal lymphnodes biopsy; chemotherapy regimens: AC, TC, AC-T/P, TCrb, TAC, capecitabine; ovarian protection:GnRHa; endocrine therapy: Aromatase inhibitor, TAM, Fulvestrant, CDK4/6 inhibitors; target therapy: trastuzumab,patuzumab, Pyrotinib.
Bisphosphonate
Bisphosphonate
RECRUITING
Peking Union Medical College Hospital, Beijing
Peking Union Medical College Hospital
OTHER